Key facts
- It has raised $78.3M; the latest was Grant ($59.0M) in Aug 2024.
- Notable investors include Mitsubishi UFJ Capital, F-Prime Capital, Eight Roads, JIC Venture Growth Investments, Kyoto University Innovation Capital — 10 tracked in total.
- Status: Privately Held (backing).
Leadership
- Donald PayanFounder
- Luis BorgesChief Scientific Officer
- Ryosuke GonotsuboChief Executive Officer & Chief Financial Officer
- Steven KatzChief Medical Officer
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Shinobi Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Shinobi Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shinobi Therapeutics
Developer of cell therapies designed for comprehensive immune evasion. The company is developing a new class of hyperimmune CD8ab iPS-T cells for cancer and other genetic diseases, providing the healthcare industry with immune therapies to treat diseases.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2015
- Employees
- 37
- Website
- shinobitx.com/
- Ownership
- Privately Held (backing)
Shinobi Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shinobi Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shinobi Therapeutics in its N-PORT filings yet. We sweep new filings monthly.